紫外线A-核黄素交联加固角巩膜安全性的研究进展  

Advanced research in the safety of UVA-riboflavin cross-linking for strengthening corneal and scleral tissue ZHAO

作　　者：赵旭[1] 王萌萌[1] 张丰菊[1] 

机构地区：[1]首都医科大学附属北京同仁医院北京同仁眼科中心北京市眼科学与视觉科学重点实验室,100730

出　　处：《中华眼科杂志》2013年第2期189-192,共4页Chinese Journal of Ophthalmology

摘　　要：紫外线A．核黄素交联法能显著提高胶原纤维的机械强度，已被用于治疗圆锥角膜等一系列角膜疾病，且有望通过增强巩膜的生物力学强度而成为治疗进行性近视的新方法。随着应用范围的不断扩展，此疗法的安全性也受到广泛关注。本文以核黄素在眼组织内的弥散过程及饱和判定为重点，分别针对交联疗法中核黄素的作用、直接光损伤、光化学损伤、交联法副作用的预防等方面进行阐述。UVA-riboflavin cross-linking is an effective approach to increase the mechanical and biochemical rigidity of the collagen fiber, which has been used in treating some corneal diseases such as keratoconus, and might become a new treatment modality for strengthening scleral tissue to prevent progressive myopia, so the safety of the new therapy has be paid attention widely. This article focus on the diffusion process and saturation judgment of riboflavin and describes the effect of riboflavin, direct UV damage, photochemical damage and the prevention of side effects in cross-linking therapy.

关 键 词：核黄素 紫外线 胶原 交联试剂 角膜基质 巩膜 

分 类 号：R772.3[医药卫生—眼科]